About AQXP

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing slated to enter Phase 3 clinical trials in 2016 for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC); a debilitating, chronic condition that is estimated to affect millions of sufferers. Aquinox has a broad intellectual property portfolio surrounding compounds that activate SHIP1
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmacies and Drug Stores

AQXP is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VXF Vanguard Extended Market ETF 6.8 B 6.8E+09 3,242 3242 0.0% 1E-05 87 K 87165
ONEQ Fidelity Nasdaq Composite Index Tracking Stock 2.0 B 2E+09 1,004 1004 0.0% 6.00456E-06 12 K 11759
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.6 B 1.85536E+10 3,550 3550 0.0% 0 16 K 15913

Wait, Before You Leave...